PMID- 37942539
OWN - NLM
STAT- MEDLINE
DCOM- 20231221
LR  - 20240208
IS  - 1522-1466 (Electronic)
IS  - 1522-1466 (Linking)
VI  - 326
IP  - 1
DP  - 2024 Jan 1
TI  - Acute high-dose MitoQ does not increase urinary kidney injury markers in healthy 
      adults: a randomized crossover trial.
PG  - F135-F142
LID - 10.1152/ajprenal.00186.2023 [doi]
AB  - Several human studies have used the mitochondrial antioxidant MitoQ. Recent in 
      vitro data indicating that MitoQ may induce nephrotoxicity caused concern 
      regarding the safety of MitoQ on the kidneys, but the doses were 
      supraphysiological. Therefore, we sought to determine whether acute MitoQ elicits 
      changes in urinary biomarkers associated with tubular injury in healthy adults 
      with our hypothesis being there would be no changes. Using a randomized crossover 
      design, 32 healthy adults (16 females and 16 males, 29 +/- 11 yr old) consumed 
      MitoQ (100-160 mg based on body mass) or placebo capsules. We obtained serum 
      samples and a 4- to 6-h postcapsule consumption urine sample. We assessed 
      creatinine clearance and urine kidney injury biomarkers including the chitinase 
      3-like-1 gene product YKL-40, kidney-injury marker-1, monocyte chemoattractant 
      protein-1, epidermal growth factor, neutrophil gelatinase-associated lipocalin, 
      interleukin-18, and uromodulin using multiplex assays. We used t tests, Wilcoxon 
      tests, and Hotelling's T(2) to assess global differences in urinary kidney injury 
      markers between conditions. Acute MitoQ supplementation did not influence urine 
      flow rate (P = 0.086, r(rb) = 0.39), creatinine clearance (P = 0.085, r(rb) = 
      0.42), or urinary kidney injury markers (T(2)(2,8) = 30.6, P = 0.121, univariate 
      ps > 0.064). Using exploratory univariate analysis, MitoQ did not alter 
      individual injury markers compared with placebo (e.g., placebo vs. MitoQ: YKL-40, 
      507 +/- 241 vs. 442 +/- 236 pg/min, P = 0.241; kidney injury molecule-1, 84.1 +/- 43.2 
      vs. 76.2 +/- 51.2 pg/min, P = 0.890; and neutrophil gelatinase-associated 
      lipocalin, 10.8 +/- 10.1 vs. 9.83 +/- 8.06 ng/min, P = 0.609). In conclusion, 
      although longer-term surveillance and data are needed in clinical populations, 
      our findings suggest that acute high-dose MitoQ had no effect on urinary kidney 
      injury markers in healthy adults.NEW & NOTEWORTHY We found acute high-dose 
      mitochondria-targeted antioxidant (MitoQ) supplementation was not nephrotoxic and 
      had no effect on markers of acute kidney injury in healthy adults. These findings 
      can help bolster further confidence in the safety of MitoQ, particularly for 
      future investigations seeking to examine the role of mitochondrial oxidative 
      stress, via acute MitoQ supplementation, on various physiological outcomes.
FAU - Linder, Braxton A
AU  - Linder BA
AUID- ORCID: 0000-0001-6825-5622
AD  - School of Kinesiology, Auburn University, Auburn, Alabama, United States.
FAU - Stute, Nina L
AU  - Stute NL
AUID- ORCID: 0000-0001-8213-638X
AD  - School of Kinesiology, Auburn University, Auburn, Alabama, United States.
FAU - Hutchison, Zach J
AU  - Hutchison ZJ
AUID- ORCID: 0000-0001-9091-5973
AD  - School of Kinesiology, Auburn University, Auburn, Alabama, United States.
FAU - Barnett, Alex M
AU  - Barnett AM
AD  - School of Kinesiology, Auburn University, Auburn, Alabama, United States.
FAU - Tharpe, McKenna A
AU  - Tharpe MA
AUID- ORCID: 0000-0002-3868-1564
AD  - School of Kinesiology, Auburn University, Auburn, Alabama, United States.
FAU - Kavazis, Andreas N
AU  - Kavazis AN
AUID- ORCID: 0000-0002-2535-7490
AD  - School of Kinesiology, Auburn University, Auburn, Alabama, United States.
FAU - Kirkman, Danielle L
AU  - Kirkman DL
AUID- ORCID: 0000-0003-1648-0662
AD  - Department of Kinesiology and Health Sciences, Virginia Commonwealth University, 
      Richmond, Virginia, United States.
FAU - Gutierrez, Orlando M
AU  - Gutierrez OM
AUID- ORCID: 0000-0001-6593-3571
AD  - Division of Nephrology, Department of Medicine, University of Alabama at 
      Birmingham, Birmingham, Alabama, United States.
FAU - Robinson, Austin T
AU  - Robinson AT
AUID- ORCID: 0000-0001-8250-3952
AD  - School of Kinesiology, Auburn University, Auburn, Alabama, United States.
LA  - eng
GR  - R15 HL165325/HL/NHLBI NIH HHS/United States
GR  - K01 HL147998/HL/NHLBI NIH HHS/United States
GR  - UL1 TR003096/TR/NCATS NIH HHS/United States
GR  - P30 DK079337/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20231109
PL  - United States
TA  - Am J Physiol Renal Physiol
JT  - American journal of physiology. Renal physiology
JID - 100901990
RN  - 0 (Lipocalin-2)
RN  - 0 (Chitinase-3-Like Protein 1)
RN  - 0 (Antioxidants)
RN  - AYI8EX34EU (Creatinine)
RN  - 47BYS17IY0 (mitoquinone)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Male
MH  - Adult
MH  - Female
MH  - Humans
MH  - Lipocalin-2/metabolism
MH  - Cross-Over Studies
MH  - Chitinase-3-Like Protein 1/metabolism
MH  - *Antioxidants/metabolism
MH  - Creatinine/metabolism
MH  - Kidney/metabolism
MH  - *Acute Kidney Injury/chemically induced/diagnosis
MH  - Biomarkers/urine
OTO - NOTNLM
OT  - acute kidney injury
OT  - cardiovascular disease
OT  - chronic kidney disease
OT  - dietary antioxidants
OT  - mitochondrial reactive oxygen species
EDAT- 2023/11/09 06:42
MHDA- 2023/12/21 06:43
CRDT- 2023/11/09 04:33
PHST- 2023/12/21 06:43 [medline]
PHST- 2023/11/09 06:42 [pubmed]
PHST- 2023/11/09 04:33 [entrez]
AID - 10.1152/ajprenal.00186.2023 [doi]
PST - ppublish
SO  - Am J Physiol Renal Physiol. 2024 Jan 1;326(1):F135-F142. doi: 
      10.1152/ajprenal.00186.2023. Epub 2023 Nov 9.